Stavudine toxicity in adult longer-term art patients in Blantyre, Malawi

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  van Oosterhout, Joep J ^a   Mallewa, Jane ^a   Kaunda, Symon ^a   Chagoma, Newton ^a   Njalale, Yassin ^a   Kampira, Elizabeth ^a,b   Mukaka, Mavuto ^a   Heydermans, Robert S ^a  

^a UNIVERSITY OF MALAWI   (Malawi)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIPODYSTROPHY; LONG TERM CARE; MALAWI; MALE; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL NEUROPATHY; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; URBAN AREA;

ADULT; ANTI-HIV AGENTS; FEMALE; HUMANS; MALAWI; MALE; MIDDLE AGED; PUBLIC POLICY; RISK FACTORS; STAVUDINE; TIME FACTORS;

EID: 84864839466     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042029     Document Type: Article

References (26)

1. Harries AD, Libamba E, Schouten EJ, Mwansambo A, Felix M, et al. ((2004)) Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis. BMJ 329:: 1163--1166.
2. Harries AD, Gomani P, Teck R, Ascurra de Teck O, Bakali E, et al. ((2004)) Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. Transactions of the Royal Society of Tropical Medicine and Hygiene 98:: 695--701.
3. Department of HIV and AIDS Ministry of Health Quarterly Report of the Antiretroviral Treatment Programme in Malawi with Results up to 31st December 2011. Department of HIV and AIDS. Lilongwe, Malawi Ministry of Health, 2012.
4. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, et al. ((2007)) Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 44:: 456--62.
5. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ, ((2011)) A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 11:: 244.
6. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, et al. ((2007)) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 101:: 793--798.
7. Mutimura E, Stewart A, Rheeder P, Crowther NJ, ((2007)) Metabolic Function and the Prevalence of Lipodystrophy in a Population of HIV-Infected African Subjects Receiving Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 46:: 451--455.
8. Bolhaar MG, Karstaedt AS, ((2007)) A High Incidence of Lactic Acidosis and Symptomatic Hyperlactatemia in Women Receiving Highly Active Antiretroviral Therapy in Soweto,. South Africa Clinical Infectious Diseases 45:: 254--60.
9. ART for HIV infection in adults and adolescents in resource-limited settings. Recommendations for a public health approach, 2010 revision. 2010; WHO Press, World Health Organization, Geneva, Switzerland.
10. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A, ((2011)) Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS 25:: 211--20.
11. Carr A, Emery S, Law M, Puls R, Lundgren JD, et al. ((2003)) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361:: 726--735.
12. Report of a WHO and IDF consultation (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. WHO Press, World Health Organization, Geneva, Switzerland.
13. Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, et al. ((2011)) Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 14:: 46.
14. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. ((2011)) Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One 6:: e18453.
15. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, et al. ((2004)) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364:: 29--34.
16. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. ((2006)) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367:: 1335--42.
17. Phidisa II Writing Team for Project Phidisa ((2010)) Ratsela A, Polis M, Dhlomo S, Emery S, et al. ((2010)) A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in SouthAfrica. J Infect Dis 202:: 1529--37.
18. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, et al. ((2010)) Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 104:: 148--53.
19. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. ((2009)) Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc 12:: 38.
20. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, et al. ((2009)) Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 48:: 1617--23.
21. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y, ((2011)) Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 56:: 59--63.
22. Hoffmann CJ, Charalambous S, Fielding KL, Innes C, Chaisson RE, et al. ((2009)) HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS 23:: 1784--1786.
23. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, et al. ((2008)) Changes in Lipid Profile Over 24 Months Among Adultson First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda. J Acquir Immune Defic Syndr 47:: 304--311.
24. Clinical management of HIV in children and adults. First Edition, July 2011. Ministry of Health, Malawi.
25. Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, et al. ((2010)) Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One 5:: e13414.
26. Somanje C (2011) Tragedy of ARVs. The Nation, 17 February (national newspaper Malawi).